Press Release
10.11.20

TOPADUR announces positive results from an interim analysis of Phase I trial

Zurich-Schlieren, Switzerland, November 10, 2020. TOPADUR Pharma AG, a biopharmaceutical start-up company today announces positive results from an analysis of the first two dose groups of the ongoing Phase 1 clinical of TOP-N53, a first-in-class wound healing drug candidate. The safety results from this interim analysis of the first two dose groups suggest that the drug was safe and well-tolerated. Moreover, data from the first two groups demonstrated an increase in skin microcirculation.

“These first results support the important role of TOP-N53 in the treatment of chronic wounds exemplified by diabetic foot ulcer (DFU) and digital ulcers (DU)”, said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG.

Download DocumentDokument herunterladen
23.3.22
Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

Read more
9.11.22
News

Scientific Publication in Pharmaceutics

Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more